New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice
- 30 September 2015
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (19), 4473-4481
- https://doi.org/10.1158/1078-0432.ccr-14-2469
Abstract
Purpose: Discriminant markers for pancreatic cancer detection are needed. We sought to identify and validate methylated DNA markers for pancreatic cancer using next-generation sequencing unbiased by known targets. Experimental Design: At a referral center, we conducted four sequential case–control studies: discovery, technical validation, biologic validation, and clinical piloting. Candidate markers were identified using variance-inflated logistic regression on reduced-representation bisulfite DNA sequencing results from matched pancreatic cancers, benign pancreas, and normal colon tissues. Markers were validated technically on replicate discovery study DNA and biologically on independent, matched, blinded tissues by methylation-specific PCR. Clinical testing of six methylation candidates and mutant KRAS was performed on secretin-stimulated pancreatic juice samples from 61 patients with pancreatic cancer, 22 with chronic pancreatitis, and 19 with normal pancreas on endoscopic ultrasound. Areas under receiver-operating characteristics curves (AUC) for markers were calculated. Results: Sequencing identified >500 differentially hyper-methylated regions. On independent tissues, AUC on 19 selected markers ranged between 0.73 and 0.97. Pancreatic juice AUC values for CD1D, KCNK12, CLEC11A, NDRG4, IKZF1, PKRCB, and KRAS were 0.92*, 0.88, 0.85, 0.85, 0.84, 0.83, and 0.75, respectively, for pancreatic cancer compared with normal pancreas and 0.92*, 0.73, 0.76, 0.85*, 0.73, 0.77, and 0.62 for pancreatic cancer compared with chronic pancreatitis (*, P = 0.001 vs. KRAS). Conclusions: We identified and validated novel DNA methylation markers strongly associated with pancreatic cancer. On pilot testing in pancreatic juice, best markers (especially CD1D) highly discriminated pancreatic cases from controls. Clin Cancer Res; 21(19); 4473–81. ©2015 AACR.Keywords
Other Versions
This publication has 38 references indexed in Scilit:
- Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesisBMC Cancer, 2012
- SAAP-RRBS: streamlined analysis and annotation pipeline for reduced representation bisulfite sequencingBioinformatics, 2012
- Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathwaysProceedings of the National Academy of Sciences of the United States of America, 2011
- Stool DNA testing for the detection of pancreatic cancerCancer, 2011
- Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic AdenocarcinomaClinical Cancer Research, 2011
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- Quantitative comparison of genome-wide DNA methylation mapping technologiesNature Biotechnology, 2010
- Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolutionNature Methods, 2010
- CpG island methylation profile of pancreatic intraepithelial neoplasiaLaboratory Investigation, 2007
- CpG Islands in vertebrate genomesJournal of Molecular Biology, 1987